Implications of baseline polymorphisms for potential resistance to NS3 protease inhibitors in Hepatitis C virus genotypes 1a, 2b and 3a

Antiviral Research

Volumn 99, Issue 1, 2013, Pages 12-17

  Palanisamy, Navaneethan ^a   Danielsson, Axel ^a   Kokkula, Chakradhar ^a   Yin, Hong ^a   Bondeson, Kåre ^a   Wesslén, Lars ^b   Duberg, Ann Sofi ^c   Lennerstrand, Johan ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b GÄVLE HOSPITAL   (Sweden)

^c ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

Author keywords

(RAVs); Hepatitis C virus; NS3 protease inhibitors; Prevalence; Resistance; Resistance associated amino acid variants

Indexed keywords

BOCEPREVIR; FALDAPREVIR; INTERFERON; NONSTRUCTURAL PROTEIN 3; PROTEINASE INHIBITOR; RIBAVIRIN; SIMEPREVIR; TELAPREVIR;

ARTICLE; BLOOD SAMPLING; CODON; GENE MUTATION; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IC 50; MAJOR CLINICAL STUDY; NUCLEOTIDE SEQUENCE; PREVALENCE; PRIORITY JOURNAL; REPLICON; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; VIRUS MUTATION; VIRUS RESISTANCE;

HEPATITIS C VIRUS;

EID: 84878116773     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2013.04.018     Document Type: Article

References (41)

1. Bacon, B.R., Gordon, S.C., Lawitz, E., Marcellin, P., Vierling, J.M., Zeuzem, S., Poordad, F., Goodman, Z.D., Sings, H.L., Boparai, N., Burroughs, M., Brass, C.A., Albrecht, J.K., Esteban, R., 2011. Boceprevir for previously treated chronic HCV genotype 1 infection. N. Engl. J. Med. 364, 1207-1217.
2. Bartels, D.J., Zhou, Y., Zhang, E.Z., Marcial, M., Byrn, R.A., Pfeiffer, T., Tigges, A.M., Adiwijaya, B.S., Lin, C., Kwong, A.D., Kieffer, T.L., 2008. Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3.4A protease inhibitors in treatment-naive subjects. J. Infect. Dis. 198, 800-807.
3. Bartels, D.J., Sullivan, J.C., Zhang, E.Z., Tigges, A.M., Dorrian, J.L., Meyer, S.D., Takemoto, D., Dondero, E., Kwong, A.D., Picchio, G., Kieffer, T.L., 2013. Hepatitis C virus variants with decreased sensitivity to direct-acting antivirals (DAAs) were rarely observed in DAA-naive patients prior to treatment. J. Virol. 87, 1544-1553.
4. Chan, K., Peng, B., Chen, X., Appleby, T.C., Taylor, J., Delaney, W.E., Cheng, G., 2012. Influence of hepatitis C virus genotype 2 subtype and NS3 polymorphisms on protease inhibitor antiviral activity. Poster 1077 Presented at the 63rd annual meeting of the AASLD, Boston, United States.
5. Danielsson, A., Palanisamy, N., Golbob, S., Yin, H., Blomberg, J., Hedlund, J., Sylvan, S., Lennerstrand, J., 2013. Transmission of hepatitis C virus among intravenous drug users in the Uppsala region of Sweden. Manuscript.
6. Duberg, A., Janzon, R., Back, E., Ekdahl, K., Blaxhult, A., 2008. The epidemiology of hepatitis C virus infection in Sweden. Euro. Surveill. 13, pii=18882.
7. Gaudieri, S., Rauch, A., Pfafferott, K., Barnes, E., Cheng, W., McCaughan, G., Shackel, N., Jeffrey, G.P., Mollison, L., Baker, R., Furrer, H., Gunthard, H.F., Freitas, E., Humphreys, I., Klenerman, P., Mallal, S., James, I., Roberts, S., Nolan, D., Lucas, M., 2009. Hepatitis C virus drug resistance and immune-driven adaptations: relevance to new antiviral therapy. Hepatology 49, 1069-1082.
8. Gravitz, L., 2011. Introduction: a smouldering public-health crisis. Nature 474, S2- S4.
9. Hadziyannis, S.J., Sette, J.H., Morgan, T.R., Balan, V., Diago, M., Marcellin, P., Ramadori, G., Bodenheimer, J.H., Bernstein, D., Rizzetto, M., Zeuzem, S., Pockros, P.J., Lin, A., Ackrill, A.M., 2004. Peginterferon-a2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann. Intern. Med. 140, 346-355.
10. Hagan, L.M., Schinazi, R.F., 2013. Best strategies for global HCV eradication. Liver Int. 33, S68-S79.
11. HCV phenotype working group, HCV drug development advisory group, 2012. Clinically relevant HCV drug resistance mutations figure and tables. Ann. Forum Collab. HIV Res. 14 (2), 1-10.
12. He, Y., King, M.S., Kempf, D.J., Lu, L., Lim, H.B., Krishnan, P., Kati, W., Middleton, T., Molla, A., 2008. Relative replication capacity and selective advantage profiles of protease inhibitor-resistant hepatitis C virus (HCV) NS3 protease mutants in the HCV genotype 1b replicon system. Antimicrob. Agents Chemother. 52, 1101- 1110.
13. Kowdley, K.V., 2005. Hematologic side effects of interferon and ribavirin therapy. J. Clin. Gastroenterol. 39, S3-S8.
14. Kuntzen, T., Timm, J., Berical, A., Lennon, N., Berlin, A.M., Young, S.K., Lee, B., Heckerman, D., Carlson, J., Reyor, L.L., Kleyman, M., McMahon, C.M., Birch, C., Schulzezur Wiesch, J., Ledlie, T., Koehrsen, M., Kodira, C., Roberts, A.D., Lauer, G.M., Rosen, H.R., Bihl, F., Cerny, A., Spengler, U., Liu, Z., Kim, A.Y., Xing, Y., Schneidewind, A., Madey, M.A., Fleckenstein, J.F., Park, V.M., Galagan, J.E., Nusbaum, C., Walker, B.D., Lake-Bakaar, G.V., Daar, E.S., Jacobson, I.M., Gomperts, E.D., Edlin, B.R., Donfield, S.M., Chung, R.T., Talal, A.H., Marion, T., Birren, B.W., Henn, M.R., Allen, T.M., 2008. Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients. Hepatology 48, 1769-1778.
15. Kwong, A.D., Najera, I., Bechtel, J., Bowden, S., Fitzgibbon, J., Harrington, P., Kempf, D., Kieffer, T.L., Koletzki, D., Kukolj, G., Lim, S., Pilot-Matias, T., Lin, K., Mani, N., Mo, H., O'Rear, J., Otto, M., Parkin, N., Pawlotsky, J.M., Petropoulos, C., Picchio, G., Ralston, R., Reeves, J.D., Schooley, R.T., Seiwert, S., Standring, D., Stuyver, L., Sullivan, J., Miller, V., 2011. Sequence and phenotypic analysis for resistance monitoring in hepatitis C virus drug development: recommendations from the HCV DRAG. Gastroenterology 140, 755-760.
16. Lagace, L., White, P.W., Bousquet, C., Dansereau, N., Do, F., Llinas-Brunet, M., Marquis, M., Massariol, M.J., Maurice, R., Spickler, C., Thibeault, D., Triki, I., Zhao, S., Kukolj, G., 2012. In vitro resistance profile of the hepatitis C virus NS3 protease inhibitor BI 201335. Antimicrob. Agents Chemother. 56, 569-572.
17. Lennerstrand, J., Bondeson, K., Bergqvist, A., Blomberg, J., Oberg, B., 2009. New antiviral agents against hepatitis C in clinical trials. Hope for a cure-but resistance problems must be overcomed. Lakartidningen 106, 3254-3256, 3258, 3260.
18. Lenz, O., Verbinnen, T., Lin, T.I., Vijgen, L., Cummings, M.D., Lindberg, J., Berke, J.M., Dehertogh, P., Fransen, E., Scholliers, A., Vermeiren, K., Ivens, T., Raboisson, P., Edlund, M., Storm, S., Vrang, L., de Kock, H., Fanning, G.C., Simmen, K.A., 2010. In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435. Antimicrob. Agents Chemother. 54, 1878-1887.
19. Lenz, O., de Bruijne, J., Vijgen, L., Verbinnen, T., Weegink, C., Van Marck, H., Vandenbroucke, I., Peeters, M., Simmen, K., Fanning, G., Verloes, R., Picchio, G., Reesink, H., 2012a. Efficacy of re-treatment with TMC435 as combination therapy in hepatitis C virus-infected patients following TMC435 monotherapy. Gastroenterology 143, 1176-1178.
20. Lenz, O., Vijgen, L., Berke, J.M., Cummings, M.D., Fevery, B., Peeters, M., Smedt, G.D., Moreno, C., Picchio, G., 2012b. Virologic response and characterization of HCV genotypes 2-6 in patients receiving TMC435 monotherapy (study TMC435- C202). J. Hepatol.. http://dx.doi.org/10.1016/j.jhep.2012.10.028.
21. Lin, C., Lin, K., Luong, Y.P., Rao, B.G., Wei, Y.Y., Brennan, D.L., Fulghum, J.R., Hsiao, H.M., Ma, S., Maxwell, J.P., Cottrell, K.M., Perni, R.B., Gates, C.A., Kwong, A.D., 2004. In vitro resistance studies of hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061. J. Biol. Chem. 279, 17508-17514.
22. Manns, M.P., McHutchison, J.G., Gordon, S.C., Rustgi, V.K., Shiffman, M., Reindollar, R., Goodman, Z.D., Koury, K., Ling, M.H., Albrecht, J.K., 2001. Peginterferon alfa- 2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358, 958-965.
23. Månsson, A.S., Moestrup, T., Nordenfelt, E., Widell, A., 2000. Continued transmission of hepatitis B and C viruses, but no transmission of human immunodeficiency virus among intravenous drug users participating in a syringe/needle exchange program. Scand. J. Infect. Dis. 32, 253-258.
24. Martell, M., Esteban, J.I., Quer, J., Genesca, J., Weiner, A., Esteban, R., Guardia, J., Gomez, J., 1992. Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: quasispecies nature of HCV genome distribution. J. Virol. 66, 3225-3229.
25. Nakano, T., Lau, G.M.G., Lau, G.M.L., Sugiyama, M., Mizokami, M., 2012. An updated analysis of hepatitis C virus genotypes and subtypes based on the complete coding region. Liver Int. 32, 339-345.
26. Norda, R., Duberg, A.S., Sönnerborg, A., Olcén, P., 1995. Transmission of hepatitis C virus by transfusion in örebro county, Sweden, 1990-1992. Scand. J. Infect. Dis. 27, 449-452.
27. Paolucci, S., Fiorina, L., Piralla, A., Gulminetti, R., Novati, S., Barbarini, G., Sacchi, P., Gatti, M., Dossena, L., Baldanti, F., 2012. Naturally occurring mutations to HCV protease inhibitors in treatment-naïve patients. Virol. J. 9, 245. http://dx.doi.org/10.1186/1743-422X-9-245.
28. Poordad, F., Chee, G., 2012. Interferon free hepatitis C treatment regimens: the beginning of another era. Curr. Gastroenterol. Rep. 14, 74-77. Prati, D., 2006. Transmission of hepatitis C virus by blood transfusions and other medical procedures: a global review. J. Hepatol. 45, 607-616.
29. Prati, D., 2006. Transmission of hepatitis C virus by blood transfusions and other medical procedures: a global review. J. Hepatol. 45, 607-616.
30. Shepard, C.W., Finelli, L., Alter, M.J., 2005. Global epidemiology of hepatitis C virus infection. Lancet Infect. Dis. 5, 558-567.
31. Shev, S., Hermodsson, S., Lindholm, A., Malm, E., Widell, A., Norkrans, G., 1995. Risk factor exposure among hepatitis C virus RNA positive Swedish blood donors - the role of parenteral and sexual transmission. Scand. J. Infect. Dis. 27, 99-104.
32. Soriano, V., Perelson, A.S., Zoulim, F., 2008. Why are there different dynamics in the selection of drug resistance in HIV and hepatitis B and C viruses? J. Antimicrob. Chemother. 62, 1-4.
33. Soriano, V., Vispo, E., Poveda, E., Labarga, P., Martin-Carbonero, L., Fernandez-Montero, J.V., Barreiro, P., 2011. Directly acting antivirals against hepatitis C virus. J. Antimicrob. Chemother. 66, 1673-1686.
34. Strahotin, C.S., Babich, M., 2012. Hepatitis C variability, patterns of resistance, and impact on therapy. Adv. Virol. 2012, 1-10.
35. Summa, V., Ludmerer, S.W., McCauley, J.A., Fandozzi, C., Burlein, C., Claudio, G., Coleman, P.J., DiMuzio, J.M., Ferrara, M., Di Filippo, M., Gates, A.T., Graham, D.J., Harper, S., Hazuda, D.J., McHale, C., Monteagudo, E., Pucci, V., Rowley, M., Rudd, M.T., Soriano, A., Stahlhut, M.W., Vacca, J.P., Olsen, D.B., Liverton, N.J., Carroll, S.S., 2012. MK-5172, a selective inhibitor of hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants. Antimicrob. Agents Chemother. 56, 4161-4167.
36. Susser, S., Welsch, C., Wang, Y., Zettler, M., Domingues, F.S., Karey, U., Hughes, E., Ralston, R., Tong, X., Herrmann, E., Zeuzem, S., Sarrazin, C., 2009. Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients. Hepatology 50, 1709-1718.
37. Susser, S., Vermehren, J., Forestier, N., Welker, M.W., Grigorian, N., Füller, C., Perner, D., Zeuzem, S., Sarrazin, C., 2011. Analysis of long-term persistence of resistance mutations within the hepatitis C virus NS3 protease after treatment with telaprevir or boceprevir. J. Clin. Virol. 52, 321-327.
38. Te, H.S., Jensen, D.M., 2010. Epidemiology of hepatitis B and C viruses: a global overview. Clin. Liver Dis. 14, 1-21.
39. Thomas, X.V., de Bruijne, J., Sullivan, J.C., Kieffer, T.L., Ho, C.K.Y., Rebers, S.P., de Vries, M., Reesink, H.W., Weegink, C.J., Molenkamp, R., Schinkel, J., 2012. Evaluation of persistence of resistant variants with ultra-deep pyrosequencing in chronic hepatitis C patients treated with telaprevir. PLoS ONE 7, e41191.
40. Welsch, C., Schweizer, S., Shimakami, T., Domingues, F.S., Kim, S., Lemon, S.M., Antes, I., 2012. Ketoamide resistance and hepatitis C virus fitness in Val55 variants of the NS3 serine protease. Antimicrob. Agents Chemother. 56, 1907- 1915.
41. Zeuzem, S., Andreone, P., Pol, S., Lawitz, E., Diago, M., Roberts, S., Focaccia, R., Younossi, Z., Foster, G.R., Horban, A., Ferenci, P., Nevens, F., Müllhaupt, B., Pockros, P., Terg, R., Shouval, D., van Hoek, B., Weiland, O., Van Heeswijk, R., De Meyer, S., Luo, D., Boogaerts, G., Polo, R., Picchio, G., Beumont, M., 2011. Telaprevir for retreatment of HCV infection. N. Engl. J. Med. 364, 2417-2428.